DRUGS AND SMOKING

DRUGS AND SMOKING

Show other versions (1)

<p>Smoking is a well – known risk factor of many diseases. It influences the efficacy and safety of drug treatment by affecting the course of different physiological processes and modifying the metabolism of drugs. The number of researches showed decrease in efficacy of some cardiovascular dru...

Full description

Bibliographic Details
Main Author:	J. V. Lukina
Format:	Article
Language:	English
Published:	Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Series:	Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:	курение эффективность и безопасность лечения сердечно-сосудистые препараты пациенты с ишемической болезнью сердца бета-адреноблокаторы
Online Access:	http://www.rpcardio.ru/jour/article/view/340

Similar Items

Lung function dynamics in smoking and non-smoking patients with stable effort angina, treated with beta-adrenoblockers
by: Yu. V. Lukina, et al.
Published: (2004-04-01)

TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2)
by: S. N. Tolpygina, et al.
Published: (2015-09-01)

USE OF BETA-BLOCKERS IN THE PERIOPERATIVE PERIOD: HOW STRONG ARE THE EVIDENCES?
by: V. V. Samoylenko, et al.
Published: (2015-09-01)

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY?
by: Yu. V. Lukina, et al.
Published: (2015-09-01)

The place of metoprolol tartrate in the treatment of cardiovascular diseases
by: N. V. Romanova, et al.
Published: (2016-12-01)

Influence of arterial hypertension, smoking, and their combination on mortality (according to the results of a 27-year cohort prospective study of the unorganized population of Tomsk)
by: I. V. Dolgalev, et al.
Published: (2019-02-01)

Optimizatsiya lecheniya patsientov s sochetannymi formami arterial'noy gipertonii i ishemicheskoy bolezni serdtsa
by: E G Volkova
Published: (2005-06-01)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

On the way toward designing next-generation nonsteroidal anti-inflammatory drugs: amtolmetin guacil
by: A.E. Karateev
Published: (2014-05-01)

MODERN PRINCIPLES OF QUALITY ASSESSMENT OF CARDIOVASCULAR DISEASES TREATMENT
by: A. Yu. Suvorov, et al.
Published: (2015-09-01)

EFFECT OF BETA-BLOCKERS ON BONE MINERAL DENSITY AND OSTEOPOROTIC FRACTURES
by: K E Sobchenko, et al.
Published: (2013-12-01)

EFFECT OF CARDIOVASCULAR DRUGS ON BONE HEALTH AND THE POSSIBILITY OF THEIR USE FOR THE PREVENTION OF OSTEOPOROSIS
by: I. A. Skripnikova, et al.
Published: (2015-12-01)

ONCE AGAIN ABOUT BETA-ADRENOBLOCKERS IN ARTERIAL HYPERTENSION. WHAT SHOULD DOCTOR RECOMMEND TO THE PATIENT?
by: S. Y. Martsevich
Published: (2016-01-01)

THE ASSESSMENT AND REDUCTION OF CARDIAC EVENTS RISK IN NONCARDIAC OPERATIONS: IS THERE A NEED FOR REVIEW OF RECOMMENDATIONS?
by: A. N. Sumin
Published: (2015-09-01)

Ведение пациента с семейной комбинированной гиперлипидемией на примере клинического случая
by: Olha Babii, et al.
Published: (2019-06-01)

RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
by: N. F. Puchinyan, et al.
Published: (2016-01-01)

TREATMENT OF CHRONIC HEART FAILURE: FOCUS ON METOPROLOL SUCCINATE
by: O. D. Ostroumova, et al.
Published: (2015-12-01)

Влияние некоторых лекарственных препаратов различных фармакологических групп на вариабельность ритма сердца
Published: (2018-06-01)

SAFETY AND EFFICACY OF EPLERENONE IN PATIENTS AT HIGH RISK FOR HYPERKALEMIA AND/OR WORSENING RENAL FUNCTION. ANALYSES OF THE EMPHASIS-HF STUDY SUBGROUPS (EPLERENONE IN MILD PATIENTS HOSPITALIZATION AND SURVIVAL STUDY IN HEART FAILURE)
by: R. Eschalier, et al.
Published: (2015-09-01)

DIHYDROPYRIDINE CALCIUM ANTAGONISTS: DATA OF EVIDENCE BASED MEDICINE AND RECOM-MENDATIONS ON PRACTICAL USE
by: S. Y. Martsevich
Published: (2015-12-01)

METABOLIC AND CARDIOVASCULAR RISKS IN WOMEN OF REPRODUCTIVE AGE WITH POLYCYSTIC OVARY SYNDROME
by: Анжелика Юрьевна Беглова, et al.
Published: (2018-12-01)

Own and parental predictors of tobacco smoking in children with early coronary heart disease
by: M. V. Konnov, et al.
Published: (2020-11-01)

Distribution of the AGT T174M and AGTR1 A1166C polymorphic markers of cardiovascular diseases among populations of Algeria, Syria and Central Russia
by: A AitAissa, et al.
Published: (2016-12-01)

TREATMENT OF HYPERTENSION IN PREGNANCY: GUIDELINES AND CLINICAL EXPERIENCE
by: O. V. Gaisenok, et al.
Published: (2015-09-01)

The pathogenic basis for the development of cardiovascular disease in obesity: difficulties of diagnosis and treatment
by: Irina Ziatovna Bondarenko, et al.
Published: (2016-03-01)

Sakharosnizhayushchie sul'fanilamidy i ?ishemicheskiy porog? serdtsa u bol'nykh sakharnym diabetom tipa 2 s koronarnoy bolezn'yu serdtsa
by: Andrey Alexeevich Aleksandrov, et al.
Published: (2002-12-01)

ДИСЛИПИДЕМИИ: ОБЗОР РЕКОМЕНДАЦИЙ ESC/EAS 2019 ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ. ЧАСТЬ 2 – ТАРГЕТНАЯ ТЕРАПИЯ
by: V. M. Pyrochkin, et al.
Published: (2021-05-01)

BETA-BLOCKERS IN THE TREATMENT OF ARTERIAL HYPERTENSION: EVIDENCE BASED DATA AND REAL PRACTICE
by: M. V. Leonova
Published: (2015-12-01)

Автоматизированная система обработки многоканальных записей электрокардиосигнала для диагностики ишемической болезни сердца
by: А.Б. Мираметов, et al.
Published: (2021-08-01)

COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
by: S. Y. Martsevich, et al.
Published: (2016-01-01)

РЕКОМЕНДАЦИИ ЕВРОПЕЙСКОГО ОБЩЕСТВА КАРДИОЛОГОВ ПО ЛЕЧЕНИЮ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БЕРЕМЕННЫХ
Published: (2016-01-01)

Prescribing nonsteroidal antiinflammatory drugs to elderly patients: questions of efficacy and safety
by: M. L. Maksimov, et al.
Published: (2015-12-01)

PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY
by: A. V. Rudakova, et al.
Published: (2015-12-01)

IZUChENIE PLEYOTROPNYKh EFFEKTOV V-ADRENOBLOKATOROV I INGIBITOROV APF NA KOSTNUYu TKAN'
by: I A SKRIPNIKOVA, et al.
Published: (2014-12-01)

STATINS IN PREVENTION OF ISCHEMIC STROKE
by: A. V. Susekov, et al.
Published: (2015-09-01)

Alogliptin – the new member of DPP-4 inhibitors class
by: Nina Aleksandrovna Petunina, et al.
Published: (2014-12-01)

Pharmacoeconomical aspects of the treatment of arterial hypertension in patients with type II diabetes mellitus in outpatient department
by: J Sh Gushina, et al.
Published: (2009-03-01)

Cardiovascular safety in the treatment of diabetes mellitus type 2: focus on alogliptin
by: A. L. Terekhova, et al.
Published: (2016-12-01)

STATINS USE IN THE PERIOPERATIVE PERIOD ACCORDING TO THE EVIDENCE-BASED MEDICINE
by: V. V. Samoylenko, et al.
Published: (2015-09-01)

The influence of surgical menopause oncardiovascular and osteoporosis risk factors(clinical observations)
by: E. Yu. Maychuk, et al.
Published: (2011-04-01)